ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Research Topic : B-Cell
Australian State/Territory : VIC
Scheme : Project Grants
Clear All
Filter by Field of Research
Cellular Immunology (6)
Basic Pharmacology (3)
Cell Development, Proliferation and Death (3)
Medical Virology (3)
Cancer Cell Biology (2)
Central Nervous System (2)
Gastroenterology and Hepatology (2)
Immunology not elsewhere classified (2)
Regenerative Medicine (incl. Stem Cells and Tissue Engineering) (2)
Signal Transduction (2)
Autoimmunity (1)
Biochemistry and Cell Biology not elsewhere classified (1)
Biological Psychology (Neuropsychology, Psychopharmacology, Physiological Psychology) (1)
Cancer Therapy (excl. Chemotherapy and Radiation Therapy) (1)
Cell Metabolism (1)
Cell Neurochemistry (1)
Cellular Interactions (incl. Adhesion, Matrix, Cell Wall) (1)
Cellular Nervous System (1)
Humoural Immunology and Immunochemistry (1)
Infectious Diseases (1)
Medical Physiology not elsewhere classified (1)
Medical and Health Sciences not elsewhere classified (1)
Molecular Targets (1)
Structural Biology (incl. Macromolecular Modelling) (1)
Tumour Immunology (1)
Filter by Socio-Economic Objective
Search did not return any results.
Filter by Funding Provider
National Health and Medical Research Council (42)
Filter by Status
Closed (42)
Filter by Scheme
Project Grants (42)
Filter by Country
Australia (42)
India (1)
Filter by Australian State/Territory
VIC (42)
ACT (2)
NSW (2)
WA (2)
QLD (1)
  • Researchers (0)
  • Funded Activities (42)
  • Organisations (36)
  • Funded Activity

    Investigating The Host Determinants Of Viral Clearance Versus Collateral Pathology In Chronic Infection

    Funder
    National Health and Medical Research Council
    Funding Amount
    $1,250,756.00
    Summary
    Hepatitis B virus has infected over 2 billion people. Some people control the virus but it remains incurable and there is a lifelong risk of liver cancer. Understanding how host cells interact with the virus, the mechanisms the cells use in an attempt to eliminate the virus and the mechanisms the virus uses to sabotage these responses, will provide insights that could lead to therapies. Potential therapies could be applicable to other infections like HIV-1 and tuberculosis.
    More information
    Funded Activity

    New Drug Combinations To Enhance Elimination Of Hepatitis B Infection

    Funder
    National Health and Medical Research Council
    Funding Amount
    $888,304.00
    Summary
    We have developed a therapy that kills hepatitis B virus infected cells and promotes elimination of infection. We are now testing novel drugs that can be used to maximise the efficacy of our new treatment to promote better outcomes that may be translated to other infections.
    More information
    Funded Activity

    Characterisation Of Anti-HBs Responses In Patients Undergoing Functional Hepatitis B Cure: Implication For Future Therapies

    Funder
    National Health and Medical Research Council
    Funding Amount
    $723,649.00
    Summary
    The hepatitis B virus causes liver cirrhosis and liver cancer. There is no cure for hepatitis B. However, a small number of patients can naturally rid themselves of the virus. We have identified 14 of these individuals and discovered that they have a unique immune response that is responsible for these “natural” cures. We plan to characterise this immune response and turn it into a therapeutic vaccine which can be used to cure patients who are still chronically infected.
    More information
    Funded Activity

    Determinants Of Sustained Virological Response After Discontinuation Of Long-term Nucleoside Analogue Therapy In Chronic Hepatitis B Patients

    Funder
    National Health and Medical Research Council
    Funding Amount
    $976,778.00
    Summary
    Guidelines currently recommend lifelong treatment for patients with chronic hepatitis B, with associated cost and risks of drug resistance and side effects. It has recently been suggested that up to 50% of patients may safely and successfully stop drug after long-term treatment. Our project will identify which patients can safely stop treatment, by performing detailed studies of the human immune system and the hepatitis B virus. This will be an important advance for patient care.
    More information
    Funded Activity

    How Do Cross-reactive Memory B Cells Affect Influenza Vaccine Titers?

    Funder
    National Health and Medical Research Council
    Funding Amount
    $798,049.00
    Summary
    Influenza vaccines are updated frequently to protect against the highly variable influenza virus. Despite careful selection of vaccine viruses, most influenza vaccines provide only modest protection and protection is poor some years. In turn, the response to vaccination varies between individuals. This probably reflects complex and variable histories of influenza infection and vaccination. The project investigates how past influenza exposure influences vaccine responses and effectiveness.
    More information
    Funded Activity

    Long Term Persistence Of HIV In The Liver And The Clinical Impact On HIV-HBV Co-infection

    Funder
    National Health and Medical Research Council
    Funding Amount
    $1,393,245.00
    Summary
    This grant will address a major question in HIV cure research - the role of the liver as an HIV reservoir and the impact of HIV persistence in HIV-infected patients on suppressive antiretroviral therapy (ART) on liver disease, in the setting of HIV-HBV co-infection. We will trial a novel intervention to reduce HIV infection of the liver that could potentially reduce chronic liver disease in this setting.
    More information
    Funded Activity

    The Mezzanine T Cell Response: Intervening At The Coal Face

    Funder
    National Health and Medical Research Council
    Funding Amount
    $765,585.00
    Summary
    In an initial immune response, specialised cells in lymph nodes tell T cells to multiply; the stimulated T cells depart and enter target tissue (e.g. lung in the case of flu). We describe a new response whereby the target tissue itself can tell T cells to multiply further. This response in target tissues reveals a new way of altering immune responses. This is especially important as in many diseases, the primary lymph node response has already occurred, so cannot be therapeutically intervened.
    More information
    Funded Activity

    Targeting Adenosine Mediated Immunosuppression To Enhance CAR T Cell Activity

    Funder
    National Health and Medical Research Council
    Funding Amount
    $633,447.00
    Summary
    The use of white blood cells genetically engineered to eradicate cancer cells specifically has been a major breakthrough in cancer treatment. These cells (CAR T cells) are very effective in blood cancers, but do not currently work well in other cancers. This is due to the immune suppressing nature of the cancer environment. I propose to use strategies to overcome this by genetically reprogramming the CAR T cells to be resistant to suppression by the cancer and therefore be more effective.
    More information
    Funded Activity

    Interplay Between Metabolic Reprogramming And Oncogenic Signalling In The Cellular Response To Chemotherapy

    Funder
    National Health and Medical Research Council
    Funding Amount
    $654,035.00
    Summary
    Chemotherapy resistance is a major barrier to the treatment of triple-negative breast cancer (TNBC). We seek to uncover an intimate link between cell metabolism and oncogenic signalling pathways in regulating the cellular response to chemotherapy. Our studies will identify a critical mechanism limiting the therapeutic efficacy of chemotherapy and investigate combination therapy strategies that could improve the treatment of TNBC.
    More information
    Funded Activity

    A Simple Method To Improve Stem Cell Transplant Therapy

    Funder
    National Health and Medical Research Council
    Funding Amount
    $831,652.00
    Summary
    Despite the success of hematopoietic stem cell transplantation and years of promise, almost all other stem cell therapies are considered experimental and remain in preclinical or early-phase clinical testing. This study aims to improve the efficiency of stem cell transplantation by manipulating cellular metabolism prior to transplantation, if effective these results may offer hope to patients suffering from a broad range of disorders.
    More information

    Showing 1-10 of 42 Funded Activites

    • 1
    • 2
    • 3
    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback